Journal articles

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

P. Saiag ^{1, *} R. Gutzmer ² P. A. Ascierto ³ M. Maio ⁴ J.-J. Grob ⁵ P. Murawa ⁶ Brigitte Dréno ^{7, 8} M. Ross ⁹ J. Weber ¹⁰ A. Hauschild ¹¹ P. Rutkowski ¹² A. Testori ¹³ E. Levchenko ¹⁴ A A Enk ¹⁵ Laurent Misery ¹⁶ C. Vanden Abeele ¹⁷ I. Vojtek ¹⁷ O. Peeters ¹⁷ V. G. Brichard ¹⁷ P. Therasse ¹⁷

* Corresponding author

1 Service de Dermatologie Générale et Oncologique [AP-HP Hôpital Ambroise-Paré, Paris]

2 Skin Cancer Center Hannover

3 National Institute for Tumors Foundation

4 Medical Oncology and Immunotherapy

5 TIMONE - Hôpital de la Timone [CHU - APHM]

6 Poznań University of Medical Sciences

7 Service de dermatologie [Nantes]

8 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers

9 MD Anderson Cancer Center [Houston]

10 H. Lee Moffitt Cancer Center & Research Institute

11 University of Kiel, UKSH

12 Maria Sklodowska Curie Memorial Center and Institute of Oncology

13 ESMO - European Institute of Oncology [Milan]

14 Petrov Research Insitut of Oncology

15 Heidelberg University

16 Dermato - BREST - Service de dermatologie

17 GSK Vaccines - Belgium

Abstract : .

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadata

https://www.hal.inserm.fr/inserm-01407384
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Friday, December 2, 2016 - 9:09:04 AM
Last modification on : Wednesday, April 27, 2022 - 4:03:40 AM
Long-term archiving on: : Thursday, March 23, 2017 - 12:01:26 AM